
CLAIMS

Claim 1: A compound of Formula (A):



(A),

or a tautomer, or a pharmaceutically acceptable salt of any of the foregoing,

wherein

R^1 is -OH;

R^2 is -C(O)H;

R^3 is C_1-C_6alkoxy or halogen;

G_1 and G_2 are each CH;

◯ indicates that the ring is aromatic;

Y^1 is C or N;

Y^2 is CH, N, NH, S, or O;

Y^3 is C or N;



















Y^4 is CH, N, NH, S, or O;

Y^5 is CR^7, N, NH, S, or O;

wherein no more than one of Y^1, Y^2, Y^3, Y^4, and Y^5 is S or O and no more than four of Y^1, Y^2, Y^3, Y^4, and Y^5 are N or NH;

R^7 is H or C_1-C_6alkyl;

n is 0, 1, 2, or 3;

R^4 is , wherein  is selected from the group consisting of , , , , , , , , , , , , , , , and ;

R^{6a}, R^{6b}, R^{6c}, and R^{6d} are each independently hydrogen, C_1-C_6alkyl, C_1-C_6alkoxy, halo, -OH, -NR^pR^q, aryl, heterocyclyl, heteroaryl, -C_1-C_6alkyl-heterocyclyl, -OC(O)-heterocyclyl, -$C(O)R^h$, -$S(O)_2NR^{w1}R^{w2}$, -$S(O)_2R^y$, or -$NR^{z1}S(O)_2R^{z2}$, wherein the C_1-C_6alkyl and C_1-C_6alkoxy of R^{6a}, R^{6b}, R^{6c}, and R^{6d} are each independently unsubstituted or substituted with one or more groups selected from the group consisting of cycloalkyl and halogen; the aryl and heteroaryl of R^{6a}, R^{6b}, R^{6c}, and R^{6d} are each independently unsubstituted or substituted with one or more groups selected from the group consisting of C_1-C_6alkyl, C_1-C_6alkoxy, C_3-C_8cycloalkyl, -OH, and C_1-C_6alkyl-OH; and the heterocyclyl, -C_1-C_6alkyl-heterocyclyl, and -OC(O)-heterocyclyl of R^{6a}, R^{6b}, R^{6c}, and R^{6d} are each independently unsubstituted or substituted with one or more groups selected from the group consisting of C_1-C_6alkyl, C_1-C_6alkoxy, halo, -OH, C_1-C_6alkyl-OH, =O, and =S;

each R^h is independently selected from the group consisting of H, C_1-C_6alkyl, C_1-C_6alkoxy, and C_3-C_8cycloalkyl, and -NR^rR^s;


each R^p is independently H or C_1-C_6alkyl;


each R^q is independently C_2-C_3alkyl, -C(O)R^t, -C(O)OR^u, or -C(O)NR^v;

each R^r, R^s, R^{w1}, and R^{z1} is independently selected from H and C_1-C_6alkyl; and

each R^t, R^u, R^v, R^{w2}, R^y, and R^{z2} is independently selected from H, C_1-C_6alkyl, unsubstituted or substituted C_3-C_8cycloalkyl, and unsubstituted or substituted heterocyclyl.


Claim 2: The compound of claim 1, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^3 is selected from the group consisting of -OCH_3, Cl, and F.

Claim 3: The compound of claim 1, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein  is selected from the group consisting of



Claim 4: The compound of claim 1, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein n is 0.

Claim 5: The compound of claim 1, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein


















is ; and











R^{6a}, R^{6b}, R^{6c}, and R^{6d} are each independently selected from the group consisting of hydrogen, C_1-C_6alkyl, C_1-C_6haloalkyl, halo, C_6-C_{12} aryl, 3- to 10-membered heterocyclyl, and 5- to 10-membered heteroaryl.











Claim 6: The compound of claim 1, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein one or more of R^{6a}, R^{6b}, R^{6c}, and R^{6d} are independently selected from the group consisting of C_1-C_6alkyl, C_1-C_6alkoxy, halo, -OH, $-NR^pR^q$, aryl, heterocyclyl, heteroaryl, -C_1-C_6alkyl-heterocyclyl, -OC(O)-heterocyclyl, $-C(O)R^h$, $-S(O)_2NR^{w1}R^{w2}$, $-S(O)_2R^y$, and $-NR^{z1}S(O)_2R^{z2}$.













Claim 7: The compound of claim 1, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is













,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,













F
HO
OHC
N
N
N
,

F
HO
OHC
N
N
N
,

F
HO
OHC
N
N
N
,

F
HO
OHC
N
N
N
,

F
HO
OHC
N
N
,

F
HO
OHC
N
N
,

F
HO
OHC
N
N
,

F
HO
OHC
N
N
,

F
HO
OHC
S
,

F
HO
OHC
S
,


F
HO
OHC
S
N
,

F
HO
OHC
O
N
N
,

F
HO
OHC
O
N
N
,

F
HO
OHC
S
N
N
,

F
HO
OHC
S
N
N
,

F
HO
OHC
N
S
N
,

F
HO
OHC
N
S
N
,

F
HO
OHC
N
N
O
N
,

F
HO
OHC
N
N
O
N
,

F
HO
OHC
N
N
S
N
,


F
HO
OHC
N
N
S
N
,

F
HO
OHC
N
N
O
,

F
HO
OHC
N
O
N
,

F
HO
OHC
N
N
S
,

F
HO
OHC
N
S
N
,

F
HO
OHC
N
S
N
N
,

F
HO
OHC
O
HN
N
N
,

F
HO
OHC
O
N
H
N
N
,

F
HO
OHC
N
N
N
N
,

F
HO
OHC
N
N
N
N
N
,

F
HO
OHC
N
N
N
N
,

F
HO
OHC
N
N
N
N
N
,


,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

, or

.

Claim 8: A pharmaceutical composition comprising at least one compound according to claim 1, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, optionally further comprising a pharmaceutically acceptable excipient.